The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib-Reference-Cited by-同舟云学术

The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib

Published:2018-07-09 Issue:5 Volume:182 Page:701-704
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Crisà Elena¹^ORCID,Cilloni Daniela²,Elli Elena M.³,Martinelli Vincenzo⁴,Palumbo Giuseppe A.⁵,Pugliese Novella⁴^ORCID,Beggiato Eloise¹,Frairia Chiara⁶^ORCID,Cerrano Marco¹,Lanzarone Giuseppe¹,Marchetti Monia⁷,Mezzabotta Mauro⁸,Boccadoro Mario¹,Ferrero Dario¹

Affiliation:

1. Haematology Division; A.O.U. Città della Salute e della Scienza di Torino; University of Turin; Torino Italy

2. Haematology Division; Department of Clinical and Biological Sciences; Ospedale San Luigi di Orbassano; University of Turin; Orbassano Italy

3. Haematology Division; Ospedale San Gerardo; ASST Monza; Monza Italy

4. Haematology Division; A.O.U Federico II; Napoli Italy

5. Haematology Division; A.O.U. Policlinico-V.Emanuele; University of Catania; Catania Italy

6. Haematology Division; Department of Translational Medicine; Azienda Ospedaliero-Universitaria Maggiore della Carita; Novara Italy

7. SOC Oncologia; Ospedale Cardinal Massaia; Asti Italy

8. Haematology Division; Ordine Mauriziano - Ospedale Umberto I; Torino Italy

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.15450/fullpdf

Reference13 articles.

1. Does ruxolitinib prolong the survival of patients with myelofibrosis?;Cervantes;Blood,2017

2. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature;Cervantes;British Journal of Haematology,2004

3. Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia;Cervantes;British Journal of Haematology,2006

4. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis;Harrison;New England Journal of Medicine,2012

5. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis;Harrison;Leukemia,2016

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of anemia in myelofibrosis: focusing on novel therapeutic options;Expert Opinion on Investigational Drugs;2023-12-10

2. The management of myelofibrosis: A British Society for Haematology Guideline;British Journal of Haematology;2023-12

3. Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety;Journal of Hematology & Oncology;2023-07-27

4. How I manage anemia related to myelofibrosis and its treatment regimens;Annals of Hematology;2023-02-14